IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i10d10.1007_s40264-022-01222-y.html
   My bibliography  Save this article

Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis

Author

Listed:
  • Monica Hoof

    (Netherlands Pharmacovigilance Centre Lareb
    Universidad de Costa Rica)

  • Katherine Chinchilla

    (Netherlands Pharmacovigilance Centre Lareb)

  • Linda Härmark

    (Netherlands Pharmacovigilance Centre Lareb)

  • Cristiano Matos

    (Instituto Politécnico De Coimbra, ESTESC-Coimbra Health School, Farmácia)

  • Pedro Inácio

    (University of Helsinki)

  • Florence Hunsel

    (Netherlands Pharmacovigilance Centre Lareb)

Abstract

Introduction Involving patients in decision making adds value in the context of pharmacovigilance (PV). This added value goes beyond participation in spontaneous reporting systems for adverse drug reactions. However, there is a gap between allowing patients to report and actual patient involvement. Views regarding best practices from regulators, patient organizations and pharmaceutical companies could help increase and improve patient involvement in PV. Objective The aim of this study was to investigate the factors contributing to best practices for patient involvement in PV and to develop a definition of patient involvement based on a qualitative multistakeholder study across Europe. Methods A literature review was conducted to map the field of study and obtain insights for the elaboration of an interview guide. Subsequently, patient representatives, members of the pharmaceutical industry and regulators were invited to participate in interviews. These interviews were analyzed using NVIVO® software and employing reflective thematic analysis. Results A total of 20 interviews were conducted with representatives at both the national and European levels. The best practices identified were engagement from the start, face-to-face communication, a full circle of feedback, same-level partners, structured involvement and guidelines, establishing common goals, patient education and empowerment, and developing trust and balance. These activities can be implemented via deep collaboration among stakeholders. A definition of patient involvement was constructed in accordance with the input of all stakeholder groups, which reflects the involvement of all types of patients at all levels of the decision-making process. Conclusion In this study, we developed a definition for patient involvement based on qualitative interviews. The factors contributing to best practices for patient involvement were mentioned across stakeholder groups and aimed to stimulate patient involvement in PV. Patients are eager to become equal partners and to engage effortlessly in the same manner as other stakeholders.

Suggested Citation

  • Monica Hoof & Katherine Chinchilla & Linda Härmark & Cristiano Matos & Pedro Inácio & Florence Hunsel, 2022. "Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis," Drug Safety, Springer, vol. 45(10), pages 1083-1098, October.
  • Handle: RePEc:spr:drugsa:v:45:y:2022:i:10:d:10.1007_s40264-022-01222-y
    DOI: 10.1007/s40264-022-01222-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01222-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-022-01222-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Manal M. Younus & Mayada Alkhakany & Priya Bahri & Angela Caro & Hadir Rostom & Helen Byomire Ndagije & Mohamed A. Elhawary, 2023. "The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is Needed," Drug Safety, Springer, vol. 46(7), pages 619-623, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:10:d:10.1007_s40264-022-01222-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.